Clinical Trial Update: An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports efficacy and safety data for paliperidone palmitate in participants with schizophrenia. The results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2013-06-17